EE141 Cost-Effectiveness of TP53 and IGHV Biomarker Testing Prior to First-Line Treatment With Novel Agents for Chronic Lymphocytic Leukemia
| Autor: | Vu, M, Degeling, K, Thompson, E, Blombery, P, Westerman, DA, IJzerman, M |
|---|---|
| Zdroj: | In Value in Health December 2022 25(12) Supplement:S80-S80 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect